TG Therapeutics, Inc. (TGTX) stock
TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/303% above fair value
$62.71−0.05 (-0.08%)
Close on Nov 17, 2026Market cap $9.60BP/E 22.9Yield –
TG Therapeutics total assets
Total assets on the balance sheet at the end of each period.
TG Therapeutics's total assets was $1.64B at Jun 30, 2026. For fiscal 2025 it was $1.06B, up 84.1% from the year before. Over ten years it grew 25.1% a year on average. The highest annual figure on record is $1.06B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.06B | +84.1% |
| FY2024 | Dec 31, 2024 | $577.69M | +75.3% |
| FY2023 | Dec 31, 2023 | $329.59M | +70.3% |
| FY2022 | Dec 31, 2022 | $193.57M | -49.0% |
| FY2021 | Dec 31, 2021 | $379.63M | -39.3% |
| FY2020 | Dec 31, 2020 | $625.64M | +283.8% |
| FY2019 | Dec 31, 2019 | $163.01M | +95.0% |
| FY2018 | Dec 31, 2018 | $83.62M | -14.1% |
| FY2017 | Dec 31, 2017 | $97.38M | +77.8% |
| FY2016 | Dec 31, 2016 | $54.78M | -51.7% |
| FY2015 | Dec 31, 2015 | $113.47M | +30.8% |
| FY2014 | Dec 31, 2014 | $86.75M | +80.3% |
| FY2013 | Dec 31, 2013 | $48.11M | +118.0% |
| FY2012 | Dec 31, 2012 | $22.07M | +51.8% |
| FY2011 | Dec 31, 2011 | $14.54M | -22.0% |
| FY2010 | Dec 31, 2010 | $18.64M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.64B | +133.4% |
| Q1 FY2026 | Mar 31, 2026 | $1.53B | +132.8% |
| Q4 FY2025 | Dec 31, 2025 | $1.06B | +84.1% |
| Q3 FY2025 | Sep 30, 2025 | $1.03B | +74.9% |
| Q2 FY2025 | Jun 30, 2025 | $702.61M | +75.1% |
| Q1 FY2025 | Mar 31, 2025 | $656.69M | +75.9% |
| Q4 FY2024 | Dec 31, 2024 | $577.69M | +75.3% |
| Q3 FY2024 | Sep 30, 2024 | $586.01M | +77.0% |
| Q2 FY2024 | Jun 30, 2024 | $401.21M | +81.7% |
| Q1 FY2024 | Mar 31, 2024 | $373.32M | +89.2% |
| Q4 FY2023 | Dec 31, 2023 | $329.59M | +70.3% |
| Q3 FY2023 | Sep 30, 2023 | $331.07M | +51.9% |
| Q2 FY2023 | Jun 30, 2023 | $220.85M | -12.2% |
| Q1 FY2023 | Mar 31, 2023 | $197.36M | -34.9% |
| Q4 FY2022 | Dec 31, 2022 | $193.57M | -49.0% |
| Q3 FY2022 | Sep 30, 2022 | $217.89M | -46.8% |
| Q2 FY2022 | Jun 30, 2022 | $251.67M | -47.7% |
| Q1 FY2022 | Mar 31, 2022 | $303.03M | -44.8% |
| Q4 FY2021 | Dec 31, 2021 | $379.63M | -39.3% |
| Q3 FY2021 | Sep 30, 2021 | $409.69M | +49.6% |
| Q2 FY2021 | Jun 30, 2021 | $481.40M | +63.4% |
| Q1 FY2021 | Mar 31, 2021 | $548.70M | +438.7% |
| Q4 FY2020 | Dec 31, 2020 | $625.64M | +283.8% |
| Q3 FY2020 | Sep 30, 2020 | $273.86M | +193.4% |
| Q2 FY2020 | Jun 30, 2020 | $294.62M | +176.4% |
| Q1 FY2020 | Mar 31, 2020 | $101.85M | -13.3% |
| Q4 FY2019 | Dec 31, 2019 | $163.01M | +95.0% |
| Q3 FY2019 | Sep 30, 2019 | $93.33M | -18.4% |
| Q2 FY2019 | Jun 30, 2019 | $106.59M | -24.3% |
| Q1 FY2019 | Mar 31, 2019 | $117.54M | -2.9% |
| Q4 FY2018 | Dec 31, 2018 | $83.62M | -14.1% |
| Q3 FY2018 | Sep 30, 2018 | $114.37M | +12.4% |
| Q2 FY2018 | Jun 30, 2018 | $140.72M | +39.0% |
| Q1 FY2018 | Mar 31, 2018 | $120.99M | -1.8% |
| Q4 FY2017 | Dec 31, 2017 | $97.38M | +77.8% |
| Q3 FY2017 | Sep 30, 2017 | $101.78M | +34.5% |
| Q2 FY2017 | Jun 30, 2017 | $101.20M | – |
| Q1 FY2017 | Mar 31, 2017 | $123.26M | – |
| Q4 FY2016 | Dec 31, 2016 | $54.78M | – |
| Q3 FY2016 | Sep 30, 2016 | $75.69M | – |
See a number that looks wrong?